Myasthenia Gravis
Core concept: Myasthenia gravis is an autoimmune disorder of postsynaptic neuromuscular transmission causing fluctuating, fatigable skeletal muscle weakness.
Key clinical distinction: Ocular, bulbar, and respiratory weakness may progress even when oxygen saturation is initially normal; serial respiratory assessments matter.
Clinical priority: Assess swallowing, secretion handling, cough, breathing effort, and progression promptly when myasthenic crisis is possible.
Etiology and Clinical Context
Definition and etiology
Myasthenia gravis (MG) is an acquired autoimmune disorder of postsynaptic neuromuscular transmission. Acetylcholine receptor (AChR) antibodies predominate; antibodies against muscle-specific kinase (MuSK) or other proteins identify additional subgroups. Thymic hyperplasia and thymoma are particularly relevant in AChR-associated disease. Coexisting autoimmune thyroid disease is possible (Shakkottai & Lomen-Hoerth, 2019).
AChR-positive versus MuSK-associated disease
Autoimmune myasthenia gravis encompasses distinct immunologic subtypes (Faktorovich & Patterson, 2019). In classic AChR-positive disease, antibodies may impair receptor function, cross-link and accelerate receptor internalization, and activate complement at the postsynaptic membrane, lowering available AChR density and end-plate safety factor. MuSK antibodies more characteristically impair organization and maintenance of acetylcholine receptor clusters through disrupted signaling at the neuromuscular junction. Bulbar and respiratory involvement may be prominent in MuSK-associated phenotypes, and response to symptomatic acetylcholinesterase inhibition can differ. The thymus is especially relevant to AChR-associated disease, but thymic pathology and therapeutic eligibility cannot be generalized uncritically to all antibody subtypes.
Disease extent, epidemiology, and antibody-negative evaluation
Ocular myasthenia involves weakness limited to extraocular and eyelid muscles at the time of assessment, whereas generalized disease also affects bulbar, limb, neck, or respiratory muscles (Shakkottai & Lomen-Hoerth, 2019). Onset can occur across adulthood, and patterns differ with age, sex, and antibody status; patients may also have other autoimmune disease or thymic abnormalities. A negative acetylcholine-receptor antibody result does not exclude myasthenia. Depending on phenotype and test availability, MuSK and other antibody evaluation, repetitive stimulation, single-fiber electrophysiology, and expert examination may be appropriate. Imaging of the anterior mediastinum evaluates for thymoma rather than explaining all fatigue syndromes.
Pathophysiology
Mechanism: loss of the safety factor
Normally, motor nerve depolarization releases acetylcholine, which binds nicotinic receptors on the muscle end plate and generates an end-plate potential sufficient to trigger a muscle action potential. In AChR-positive MG, antibody-mediated receptor loss, complement injury, and simplification of postsynaptic folds reduce that safety margin. Repeated activity can expose transmission failure, producing fatigability. MuSK-associated disease disrupts receptor clustering through a different mechanism; it should not be described as simply complement-mediated AChR destruction (Shakkottai & Lomen-Hoerth, 2019).
Clinical Manifestations
Clinical manifestations and localization
Fluctuating ptosis and diplopia, chewing fatigue, nasal or dysarthric speech, dysphagia, neck weakness, and proximal limb weakness are characteristic (Faktorovich & Patterson, 2019). Symptoms commonly worsen with sustained activity and improve after rest. Sensation and deep tendon reflexes are typically preserved. Respiratory muscle impairment and bulbar dysfunction can precipitate a life-threatening myasthenic crisis.
Diagnostic Evaluation
Diagnostic approach
Antibody testing and repetitive nerve stimulation or single-fiber electromyography support diagnosis; a decremental response indicates impaired transmission (Faktorovich & Patterson, 2019). Ice-pack improvement in ptosis is supportive, not definitive. Chest imaging evaluates for thymoma. Consider Lambert–Eaton syndrome (often reduced reflexes and facilitation), botulism (autonomic and pupillary findings), and primary myopathies or central disease. Antibody sensitivity varies by MG phenotype.
Interpret serology and electrophysiology within phenotype
AChR-binding antibodies are highly informative in a compatible ocular or generalized fatigability phenotype, but absence of detectable AChR antibodies does not exclude MG (Faktorovich & Patterson, 2019). MuSK testing, additional antibody testing where available, and targeted electrodiagnostic evaluation may be considered when suspicion persists. Repetitive nerve stimulation demonstrates a decremental compound muscle action potential in susceptible muscles; single-fiber EMG assesses increased neuromuscular jitter and is sensitive but not disease-specific. Obtain appropriate chest imaging when evaluating for thymoma. The ice-pack test can transiently improve ptosis but is supportive rather than a replacement for clinical and laboratory confirmation.
Clinical urgency is driven by trajectory, secretion handling, swallowing, voice, cough, work of breathing, and objective respiratory muscle measurements (Faktorovich & Patterson, 2019). Vital capacity and negative inspiratory force are contextual measures; a single value is not a universally safe intubation threshold. Normal oxygen saturation may persist until late in ventilatory weakness. Early critical-care and neurology assessment is warranted for progressive bulbar or respiratory findings.
Differential Diagnosis
Myasthenic versus cholinergic deterioration
Myasthenic crisis arises from failure of neuromuscular transmission and may be precipitated by infection, medication exposure, surgery, or other physiologic stress (Faktorovich & Patterson, 2019). Excessive cholinesterase inhibition can produce cholinergic toxicity with weakness plus muscarinic features such as salivation, sweating, diarrhea, bronchorrhea, and bradycardia, and possible fasciculations. Cholinergic crisis is much less common in contemporary routine MG practice and should not be assumed from weakness alone. Both require urgent stabilization and careful medication review. The distinction is clinical and treatment-relevant; do not delay airway support while attempting to classify the crisis definitively.
Treatment and Management
Treatment rationale and crisis
Pyridostigmine increases acetylcholine availability for symptomatic relief (Faktorovich & Patterson, 2019). Glucocorticoids and steroid-sparing immunotherapies modify the immune process; thymectomy is indicated for thymoma and selected nonthymomatous generalized AChR-positive MG. IV immunoglobulin or plasma exchange provides faster immunomodulation in severe exacerbations. Respiratory evaluation incorporates serial vital capacity, inspiratory force, bulbar function, work of breathing, secretion handling, and clinical trajectory—no isolated numeric cutoff replaces bedside assessment. Cholinergic toxicity from excessive acetylcholinesterase inhibition is a distinct differential, not an assumed cause of deterioration.
Complications and Red Flags
Myasthenic crisis: physiological monitoring and escalation
Myasthenic crisis results from inadequate neuromuscular transmission with respiratory or bulbar weakness, often precipitated by infection, surgery, or medication-related stress (Faktorovich & Patterson, 2019). Bedside assessment integrates speech, swallowing, cough, secretion control, work of breathing, serial vital capacity and inspiratory strength, and overall trajectory. Pulse oximetry can remain normal until late in isolated ventilatory muscle failure. Numerical respiratory thresholds are supportive data, never a stand-alone intubation rule. Review potentially aggravating medications (including selected antibiotics and magnesium) according to clinical necessity. Escalate early for threatened airway protection or ventilation; plasma exchange or intravenous immunoglobulin and respiratory support are specialist-led options. Cholinergic toxicity is an uncommon alternate explanation and may add prominent muscarinic manifestations.
Myasthenic crisis: interpret respiratory trends rather than saturation
An apparently normal oxygen saturation or arterial blood gas does not establish adequate ventilatory reserve in myasthenia gravis (Faktorovich & Patterson, 2019). Progressive diaphragmatic weakness may precede hypoxemia or hypercapnia. Serial forced vital capacity and negative inspiratory force, respiratory effort, cough and secretion clearance, dysphagia, orthopnea, and the trajectory of weakness must be interpreted together. The Myasthenia Gravis Foundation of America emphasizes trends and clinical context rather than isolated thresholds; deteriorating airway protection or ventilation warrants urgent intensive-care evaluation (Myasthenia Gravis Foundation of America [MGFA], n.d.).
Treatment mechanisms differ by disease phenotype. Pyridostigmine increases acetylcholine availability, plasma exchange or IV immunoglobulin can provide short-term rescue in severe exacerbation, and immunotherapies address autoimmunity over different time scales. FcRn antagonism reduces recycling of pathogenic IgG. Nipocalimab-aahu (Imaavy), a neonatal Fc receptor blocker, is indicated for generalized MG in patients aged 12 years and older who are AChR- or MuSK-antibody positive. Its IgG-lowering mechanism does not replace airway management, plasma exchange, or IV immunoglobulin when ventilatory or bulbar function is acutely threatened. Before treatment, evaluate vaccination status and active infection; monitor for infection, hypersensitivity, and infusion-related reactions. Live vaccines are not recommended during treatment (U.S. Food and Drug Administration, 2026).
Clinical Reasoning Priorities
Applied case: weakness and threatened ventilation
A patient with intermittent ptosis and chewing fatigue becomes dysarthric during a respiratory infection and cannot speak comfortably in complete sentences. Preserved sensation and activity-dependent weakness localize toward neuromuscular junction disease. AChR serology and electrophysiology support diagnosis, but immediate priorities are secretion handling, cough, swallowing, serial respiratory assessment, and escalation for potential myasthenic crisis. Normal pulse oximetry early in the course does not exclude impending ventilatory failure. A medication review is essential because selected therapies can worsen transmission.
Related YourDNP Guides
For related clinical reasoning, see Motor Neuron Diseases and Seizure Disorders.
Content last reviewed:
References
Faktorovich, S., & Patterson, S. K. (2019). Myasthenia gravis and other disorders of the neuromuscular junction. In J. C. M. Brust (Ed.), CURRENT diagnosis & treatment: Neurology (3rd ed.). McGraw-Hill Education.
Myasthenia Gravis Foundation of America. (n.d.). Emergency management for first responders. https://myasthenia.org/understanding-mg/learn-more-about-mg-treatments/mg-brochures/emergency-management-for-first-responders/
Shakkottai, V. G., & Lomen-Hoerth, C. (2019). Nervous system disorders. In G. D. Hammer & S. J. McPhee (Eds.), Pathophysiology of disease: An introduction to clinical medicine (8th ed.). McGraw-Hill Education.
U.S. Food and Drug Administration. (2026). Imaavy (nipocalimab-aahu) injection: Prescribing information (revised August 2026). https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761430s002lbl.pdf